C - reactive protein and interleukin - 6 levels among human immunodeficiency virus -infected patients with dysglycemia in Tanzania

Abstract We used generalized estimating equations to quantify the impact of recent vaccination or intercurrent infections on immune and inflammatory biomarkers among 144 human immunodeficiency virus (HIV)-infected adults with HIV RNA < 50 copies/mL on antiretroviral therapy. These events were associated with a 2.244 µg/mL increase in high sensitivity C-reactive protein and should be routinely assessed in future studies.

Download Full-text

Clinical Outcomes and Immunologic Characteristics of Coronavirus Disease 2019 in People With Human Immunodeficiency Virus

The Journal of Infectious Diseases ◽

10.1093/infdis/jiaa380 ◽

2020 ◽

Cited By ~ 3

Author(s):

Hsi-en Ho ◽

Michael J Peluso ◽

Colton Margus ◽

Joao Pedro Matias Lopes ◽

Chen He ◽

...

Keyword(s):

At Risk ◽

Human Immunodeficiency Virus ◽

Inflammatory Markers ◽

C Reactive Protein ◽

Reactive Protein ◽

Markers Of Inflammation ◽

Cell Counts ◽

Immunodeficiency Virus ◽

Factor Α ◽

Necrosis Factor

Abstract We performed a retrospective study of coronavirus disease 2019 (COVID-19) in people with human immunodeficiency virus (PWH). PWH with COVID-19 demonstrated severe lymphopenia and decreased CD4+ T cell counts. Levels of inflammatory markers, including C-reactive protein, fibrinogen, D-dimer, interleukin 6, interleukin 8, and tumor necrosis factor α were commonly elevated. In all, 19 of 72 hospitalized individuals (26.4%) died and 53 (73.6%) recovered. PWH who died had higher levels of inflammatory markers and more severe lymphopenia than those who recovered. These findings suggest that PWH remain at risk for severe manifestations of COVID-19 despite antiretroviral therapy and that those with increased markers of inflammation and immune dysregulation are at risk for worse outcomes.

Download Full-text

Analysis cluster of differentiation 4 number and c-reactive protein concentration in patient with human immunodeficiency virus with or without lung tuberculosis

IOP Conference Series Earth and Environmental Science ◽

10.1088/1755-1315/125/1/012001 ◽

2018 ◽

Vol 125 ◽

pp. 012001

Author(s):

M J Nur ◽

F Kuhuwael ◽

S Katu ◽

H Mubin ◽

R Halim

Keyword(s):

Human Immunodeficiency Virus ◽

Protein Concentration ◽

C Reactive Protein ◽

Reactive Protein ◽

Lung Tuberculosis ◽

Immunodeficiency Virus ◽

Cluster Of Differentiation

Download Full-text

Plasma Biomarkers of Human Immunodeficiency Virus–Related Systemic Inflammation and Immune Activation in Sub-Saharan Africa Before and During Suppressive Antiretroviral Therapy

The Journal of Infectious Diseases ◽

10.1093/infdis/jiz252 ◽

2019 ◽

Vol 220 (6) ◽

pp. 1029-1033 ◽

Cited By ~ 14

Author(s):

Stefanie Kroeze ◽

Ferdinand W Wit ◽

Theresa M Rossouw ◽

Helen C Steel ◽

Cissy M Kityo ◽

...

Keyword(s):

Human Immunodeficiency Virus ◽

Antiretroviral Therapy ◽

Immune Activation ◽

Protein C ◽

C Reactive Protein ◽

Lipopolysaccharide Binding Protein ◽

Reactive Protein ◽

Art Initiation ◽

Immunodeficiency Virus ◽

Lipopolysaccharide Binding

AbstractWe evaluated immune biomarker profiles in human immunodeficiency virus (HIV)–infected adults (n = 398) from 5 African countries. Although all biomarkers decreased after antiretroviral therapy (ART) initiation, levels of C-X-C chemokine ligand 10 (CXCL10), lipopolysaccharide-binding protein, C-reactive protein, soluble CD163, and soluble scavenger receptor CD14 were significantly higher during ART than in an HIV-uninfected reference group (n = 90), indicating persistent monocyte/macrophage activation, inflammation, and microbial translocation. Before ART initiation, high HIV viral load was associated with elevated CXCL10 and tuberculosis coinfection was associated with elevated soluble CD14. High pre-ART levels of each biomarker strongly predicted residual immune activation during ART. Chemokine (C-C motif) ligand 2, lipopolysaccharide-binding protein, C-reactive protein, and interleukin 6 were differentially expressed between countries. Further research is needed on the clinical implications of residual immune dysregulation.

Download Full-text